Gelteq IPO: Supporting Gel Technology for Oral Drug Delivery
XTalks
NOVEMBER 6, 2024
The stable gel matrix holds multiple ingredients, offering targeted release and enhanced bioavailability while optimizing patient experience. This regulatory strategy leverages bioequivalence studies to expedite approval, positioning Gelteq’s gel as an alternative to traditional oral delivery forms.
Let's personalize your content